https://orcid.org/0000-0002-2789-8290
References
- Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol. 2000 Nov;43(5 Pt 1):841–847.
- Davis MDP, Fallon WMO, Iii RSR, et al. Natural History of Erythromelalgia. Arch Dermatol. 2000;136(3):330–336.
- Mørk C, Kvernebo K, Asker CL, et al. Reduced skin capillary density during attacks of erythromelalgia implies arteriovenous shunting as pathogenetic mechanism. J Invest Dermatol. 2002;119(4):949–953.
- Drenth JP, Te Morsche RH, Guillet G, et al. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol. 2005 Jun;124(6):1333–1338.
- Michiels JJ, Drenth JP, Van Genderen PJ. Classification and diagnosis of erythromelalgia and erythermalgia. Int J Dermatol. 1995 February;34(2):97–100. PMID 7737785. .
- Cimolai N, Cimolai T. Erythromelalgia accompanying rosuvastatin-associated myopathy. J Dermatol Case Rep. 2009 Apr 5;3(1):1–3.